ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print
Health Technology

Sumitomo Pharma Co., Ltd.

Business Summary

Sumitomo Pharma Co., Ltd. engages in manufacture, sale, import, and export of pharmaceutical products. It operates through the Pharmaceutical Business and Other Business segments. The Pharmaceutical Business segment manufactures and sells generic and prescription drugs in Japan, North America, China, and other overseas countries. The Other Business segment division includes food ingredients, additives, chemical products, veterinary drugs, and diagnostic reagents. The company was founded on May 14, 1897 and is headquartered in Osaka, Japan.

Financial Highlights

Mar 2022 JPYUSD
Gross Profit371,177M3,303.08M
Operating income56,553M503.26M
Income before tax82,961M738.26M
Net income56,413M502.01M
Diluted EPS141.991.26
Dividends Per Share280.24
Total Assets1,308.00B10,776.57M
Total liabilities634,438M5,227.08M
Total equity607,888M5,008.34M
Operating cash flow31,239M277.99M
Currency in JPYCurrency in USD

Historical Data

 Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022
Revenue 466,838M 459,267M 482,732M 515,952M 560,035M
Gross Profit 347,955M 337,856M 341,787M 361,600M 371,177M
Operating income 79,643M 57,207M 51,083M 68,381M 56,553M
Income before tax 84,866M 65,046M 83,947M 77,851M 82,961M
Net income 53,448M 48,627M 40,753M 56,219M 56,413M
EBITDA 92,530M 71,183M 68,448M 91,054M 94,901M
Diluted EPS 134.53 122.39 102.57 141.50 141.99
Dividends Per Share 28 28 28 28 28
Total Assets 809,684M 834,717M 1,256.53B 1,308.12B 1,308.00B
Total liabilities 356,961M 336,555M 620,674M 659,949M 634,438M
Total equity 452,723M 498,138M 532,670M 580,570M 607,888M
Operating cash flow 93,420M 48,711M 46,128M 135,601M 31,239M
 Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022
Revenue 4,212.10M 4,141.47M 4,439.90M 4,864.83M 4,983.72M
Gross Profit 3,139.46M 3,046.63M 3,143.56M 3,409.47M 3,303.08M
Operating income 718.58M 515.86M 469.83M 644.75M 503.26M
Income before tax 765.71M 586.55M 772.09M 734.04M 738.26M
Net income 482.24M 438.49M 374.82M 530.08M 502.01M
EBITDA 834.86M 641.89M 629.54M 858.53M 844.52M
Diluted EPS 1.21 1.10 0.94 1.33 1.26
Dividends Per Share 0.25 0.25 0.25 0.26 0.24
Total Assets 7,613.38M 7,541.37M 11,639.42M 11,838.25M 10,776.57M
Total liabilities 3,356.47M 3,040.65M 5,749.37M 5,972.38M 5,227.08M
Total equity 4,256.91M 4,500.50M 4,934.18M 5,254.02M 5,008.34M
Operating cash flow 842.89M 439.25M 424.26M 1,278.56M 277.99M

Valuation Measures

Mar 2022
Operating margin10.09%
Profit margin10.07%

Key executives

  • President, Chief Executive Officer & Director: Hiroshi Nomura
  • Director, Head-Research & Technology: Yoshiharu Ikeda
  • Executive Officer & GM-Technology Research: Kenji Ueno
  • Executive Officer & Senior Research Director: Isao Shimizu
  • Managing Executive Officer: Shigeyuki Nishinaka


  • Sumitomo Chemical Co., Ltd. (51.6%)
  • Nomura Asset Management Co., Ltd. (3.5%)
  • Inabata & Co., Ltd. (3.0%)
  • Nippon Life Insurance Co. (1.9%)
  • Nikko Asset Management Co., Ltd. (1.7%)
  • Sumitomo Mitsui Banking Pension Fund (1.7%)
  • Daiwa Asset Management Co. Ltd. (1.7%)
  • Sumitomo Life Insurance Co. (1.4%)
  • The Vanguard Group, Inc. (1.0%)
  • Mitsubishi UFJ Kokusai Asset Management Co., Ltd. (0.9%)

Contact Details

Related Companies

  • Sumitomo Pharma Employee Stock Ownership Plan
  • Sumitomo Pharma Oncology, Inc.
  • Spirovant Sciences Ltd.
  • DS Pharma Promo Co., Ltd.
  • Enzyvant Therapeutics Ltd.
  • Sumitomo Dainippon Pharma Oncology, Inc.
  • Sumitovant Biophama, Inc.
  • Sumitovant Biopharma Ltd. (London)
  • Sumitovant Biopharma Ltd.
  • Sumitomo Pharma Pension Fund
  • Urovant Sciences Ltd.
  • Myovant Sciences Ltd.
  • Sumitomo Dainippon Pharma America, Inc.
  • Sunovion Pharmaceuticals Asia Pacific Pte Ltd.
  • Sumitomo Pharmaceuticals (Suzhou) Co., Ltd.
  • Sumitomo Dainippon Pharma Trust
  • Sumitomo Pharma Food & Chemical Co., Ltd.
  • DS Pharma Animal Health Co., Ltd.
  • Sumitomo Dainippon Pharma Employee Stock Ownership Plan
  • Kyowa Hakko Pharmaceuticals (Suzhou) Co. Ltd.
  • Tanabe Seiyaku Co., Ltd. /Pet Medicine Operations/
  • Tolero Pharmaceuticals, Inc.
  • Boston Biomedical, Inc.
  • Sunovion Pharmaceuticals, Inc.


  • Vanda Pharmaceuticals Inc.
  • Cerevel Therapeutics Holdings Inc
  • ACADIA Pharmaceuticals Inc.
  • Intra-Cellular Therapies, Inc.
  • Voyager Therapeutics, Inc.
  • Alkermes Plc
  • Innoviva, Inc.
  • Karuna Therapeutics, Inc.
  • Acorda Therapeutics, Inc.
  • Impel Pharmaceuticals Inc.
  • Gongwin Biopharm Holdings Co., Ltd.
  • SyneuRx International (Taiwan) Corp.
  • Verona Pharma plc Sponsored ADR
  • Bright Minds Biosciences Inc.
  • ATAI Life Sciences N.V.
  • VistaGen Therapeutics, Inc.
  • Supernus Pharmaceuticals, Inc.
  • Aerovate Therapeutics, Inc.
  • Aravive, Inc.
  • Aytu BioPharma, Inc.
  • BioLineRX Ltd.
  • Biomea Fusion Inc
  • Cyclacel Pharmaceuticals, Inc.
  • FutureChem Co., Ltd.
  • Geron Corporation
  • Gossamer Bio, Inc.
  • Kronos Bio Inc
  • Kura Oncology, Inc.
  • Marinus Pharmaceuticals Inc
  • OptiNose, Inc.
Last Updated on 26 Jan, 2023

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more